Navigation Links
A ton of bitter melon produces sweet results for diabetes
Date:3/27/2008

Practitioners of Chinese medicine have used it for hundreds of years to good effect.

Garvan has a formal collaborative arrangement with the Shanghai Institute of Materia Medica. In addition to continuing to work together on the therapeutic potential of bitter melon, we will be exploring other Chinese medicines.

Professor Yang Ye, from the Shanghai Institute and a specialist in natural products chemistry, isolated the different fractions from bitter melon and identified the compounds of interest.

Bitter melon was described as bitter in taste, non-toxic, expelling evil heat, relieving fatigue and illuminating in the famous Compendium of Materia Medica by Li Shizhen (1518-1593), one of the greatest physicians, pharmacologists and naturalists in Chinas history, said Professor Ye. It is interesting, now that we have the technology, to analyse why it has been so effective.

Some of the compounds we have identified are completely novel. We have elucidated the molecular structures of these compounds and will be working with our colleagues at Garvan to decipher their actions at a molecular level. We assume its working through a novel pathway inside cells, and finding that pathway is going to be very interesting.


'/>"/>

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Research Australia
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Food peptides activate bitter taste receptors
2. Mouse model for mesothelioma reproduces human disease
3. HealthMedia Fourth Quarter 2007 Produces Highest Revenue in Company History
4. Aggressive Therapy for Crohns Disease Produces Better Outcomes
5. Taxol with avastin produces noteworthy results
6. Stem cell research produces a key discovery for Fragile X Syndrome
7. Photo: Sweet Dreams From Turkey
8. New Web Site Lets You Test Your Sweet-Smarts Just in Time for Valentines Day and Easter
9. Artificial sweeteners linked to weight gain
10. Sunsweet Introduces PlumSmart Light(R)
11. Looking For Some Sweet and Healthy Stocking Stuffers?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Call/ -- Cyberonics, Inc. (Nasdaq: CYBX ),today...cutive Officer, and,Greg Browne, Vice President, ...,at the Piper Jaffray 20th Annual Health Care Conf...t 1:00 PM EST. The conference session and webcast...presented. Piper Jaffray will,host a webcast of ...
(Date:11/21/2008)...e-USNewswire/ -- The U.S. Department of Health and...t Safety Organizations (PSOs). , , The rul...final requirements and procedures for PSOs, new en...iders can work to collect, aggregate and analyze d...lege and confidentiality protections - to identify...
(Date:11/21/2008)...r disease are not given adequate drug therapy. Thi...current edition of Deutsches rzteblatt Internatio...Uwe Zeimer et al. present the German results of th...n Germany took part in the study. They enrolled 55...e or more cardiovascular diseases and 10.8% only e...
(Date:11/21/2008)...ita Picozzi Moran has joined the Dallas office of ...or her work in academic architecture, will strengt...ractice and broaden the talent base in the growing...and skills complement our team in Dallas and exten... clients," said Mark W. Vaughan AIA, ACHA, Princip...
Breaking Medicine News(10 mins):Health News:Cyberonics to Present at Piper Jaffray 20th Annual Health Care Conference 2Health News:Final Rule Issued for Patient Safety Organizations 2Health News:Final Rule Issued for Patient Safety Organizations 3Health News:Anita Moran AIA Joins WHR Dallas 2
...sity Hospital recently performed for the first tim...nd Assisted Thrombolysis to destroy a deadly bloo...bosis. The procedure was performed by Abbas Chams...terventional radiology in the Emory University Sch...
...es, Indrajit Roy wanted to get the best cure at an...sed to remove the stone in a bloodless laser-aide...her hospitals, his prayers were answered. Roy, 32...ity's Anandalok Charitable Hospital, in Salt Lake,...
...pplements have skyrocketed by 100 percent in the U...eople dont consider evidence-based indications bef...study published in this months Mayo Clinic Proceed...herbs dont do so in accordance with scientific gui...
...ho killed their friend and buried her under a hous...ednesday . They cant be let out on prole till they... cannot be named because of their age, pleaded gui...rder of Eliza Jane Davis last June. Perth Childr...
Other Medicine News:Health News:First Ultrasound Thrombolysis in U.S. Performed at Emory University Hospital 2Health News:Two Australian Teenagers Sentenced to Life for Murder 2
(Date:11/21/2008)...if., Nov. 21 Amgen,(Nas...mmittee for Medicinal,Products for Human Use (CHM...keting authorisation for Nplate(TM) (romiplostim) ...Nplate for adult chronic immune (idiopathic),thro... who are refractory to,other treatments (e.g. cor...
(Date:11/21/2008)...d, November 21 , ...mittee for Medicinal Products for Human Use (CHMP)...the approval of Enbrel(R),(etanercept) as a treat...scents with severe plaque psoriasis. If approved b...e,s recommendation, Enbrel will become the,first ...
(Date:11/21/2008).... 21 Ikaria Holdings, Inc. today a... the Year by the New Jersey Technology Council (NJ...rovides business support, networking opportunities...s and their leaders. Ikaria earned the award based...e product/service provision. , , "We are de...
(Date:11/20/2008)..., Nov. 20 Epeius Biotechnologies,...tudies of Rexin-G in,chemotherapy-resistant metas...esented by Dr. Sant P. Chawla, principal investiga...don UK on November 13-15, 2008. Patients received,...up to 9 months. Analysis of,safety and efficacy d...
Breaking Medicine Technology:Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 2Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 3Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 4Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 5Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 6Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 7Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 8CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2Diabetes could be a hidden condition for heart disease patients 24026 1How birds spot the cuckoo in the nest 4043 1How birds spot the cuckoo in the nest 4043 2Pfizer inks global license to Genomatix Software and databases 4041 1Hennepin County Minnesota Selects Lagan Human Services 28TM 29 to Support Human Services and Public Health Department e Government Initiative 24024 1Hennepin County Minnesota Selects Lagan Human Services 28TM 29 to Support Human Services and Public Health Department e Government Initiative 24024 2Hennepin County Minnesota Selects Lagan Human Services 28TM 29 to Support Human Services and Public Health Department e Government Initiative 24024 3
...strated in Lung and Colorectal Cancers, ROCKVILLE,...reMed, Inc. , a clinical-stage pharmaceutical comp...ancer and inflammatory diseases,announced the pre...nhibitor compounds. The data were presented by Ent...ancer Research (AACR) Annual,Meeting in Los Angele...
...-(BUSINESS WIRE)--Apr 16, 2007 - Amgen,(Nasdaq:AMG...double-blind, placebo-controlled Phase 3 study eva...bepoetin alfa) for the,treatment of anemia in pati... or radiotherapy ("the 103 study"). Aranesp is not...ents. These,results were presented in an oral sess...
Other Medicine Technology:EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models 2EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models 3EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7
Suture Retriever, 15 Up
...er is for arthroscopic and open soft tissue repair...complicated procedural steps. It may be used with...ction with,anchors or screws (including suture pre...ip permits the placement of a variety of stitch pa...
The Nordt Knot Tightener allows both pushing and spreading of knots, reproducing identical techniques,used when tying traditional open knots. The Nordt Knot Tightener allows tying of any type of s
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture.
Medicine Products: